Collegium Pharmaceutical, Inc. (COLL) Q2 FY26 Earnings Call

ADHD momentum is accelerating, but Nucynta pricing pressure leaves adjusted EBITDA guidance essentially flat.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-06
Length34 minutes
EPS$1.57
EPS consensus$1.48
Revenue$199.9M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All COLL earnings ยท Back to COLL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.